Steve Fawell

Apr 23, 2024 | drugdiscoveryonline.com | Steve Fawell |Jean-Sebastien Steffen |Dan Bowles

Progress with PROTACs and molecular glues hasn’t come without challenges, particularly in identifying the right chemistry starting point for drug development — a process known as hit discovery. This article looks at the role of CRISPR, screening assays, and more.

Mar 7, 2024 | drugdiscoveryonline.com | Steve Fawell

By Steve Fawell, AstraZeneca We recently described how advances in small molecule drug discovery are allowing us to rethink and expand the list of therapeutic targets that may be druggable in oncology.1 This includes progress with platforms like PROteolysis TArgeting Chimeras (PROTACs) and molecular glues, which are opening new possibilities for targeting “undruggable” proteins that have long been known to play a role in cancer.1–5 (Check out my first two articles in this series:...

Jan 18, 2024 | drugdiscoveryonline.com | Steve Fawell

By Steve Fawell, AstraZeneca Undruggable — it’s a word that has haunted drug discoverers across all types of diseases for many years, especially in oncology.1 Undruggable targets for cancer often refer to specific proteins or biomolecules that play a role in the development and progression of cancer and have evaded treatment with currently available therapies.1 They may play a key role in directing signaling molecules involved in disease progression, be proteins with scaffolding functions, or...

Oct 22, 2023 | drugdiscoveryonline.com | Steve Fawell

Guest Column | February 9, 2024 By Steve Fawell, AstraZeneca In drug discovery, “undruggables” are proteins or biomolecules identified as playing a role in the development or progression of diseases – such as cancer – but are challenging to target pharmacologically.1 With the development of novel precision medicines and innovative therapeutic approaches, we are making great progress in overcoming various factors that make these targets undruggable, with new options for patients on the...